APRIL inhibitors(Tumor necrosis factor ligand superfamily member 13 inhibitors), BAFF inhibitors(B-cell-activating factor/B lymphocyte stimulator inhibitors), Immunomodulators

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesNeoplasms+ [7]

Active Indication

Myasthenia GravisRheumatoid ArthritisSystemic Lupus Erythematosus+ [10]

Inactive Indication-

Originator Organization

RemeGen Co., Ltd.

Active Organization

RemeGen Co., Ltd.

Vor Biopharma, Inc.

Inactive Organization-

License Organization

Vor Biopharma, Inc.

RemeGen Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

China (09 Mar 2021),

Systemic Lupus Erythematosus

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China)

Structure/Sequence

Sequence Code 616721115

Source: *****

Clinical Trials associated with Telitacicept

NCT07052981

/ Not yet recruitingPhase 3IIT

Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis

This clinical trial is a prospective, multicenter, non-randomized controlled study designed to evaluate the efficacy and safety of Telitacicept, a novel biologic agent, in treating pediatric IgA Nephropathy (IgAN) and IgA Vasculitis Nephritis (IgAVN). The study plans to enroll 124 children aged 5-18, divided into a test group (standard therapy + Telitacicept) and a control group (standard therapy alone), with a 24-week treatment period. The primary endpoint is the change in 24-hour urine protein levels at week 24, while secondary outcomes include UPCR (urine protein-to-creatinine ratio), eGFR, and drug safety.

Start Date01 Aug 2025

Sponsor / Collaborator

Nanjing Children's Hospital Ltd.

NCT07077486

/ Enrolling by invitationPhase 4IIT

A Randomized, Positvel Controlled, Multicenter Study of Effects of Telitacicept vs Cyclophosphamide on Lupus Realted Interstitial Lung Disease

Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and clinical ILD in patients with early lupus.

Start Date25 Jul 2025

Sponsor / Collaborator

Tongji Hospital Tongji Medical College of HUST

[+2]

NCT07111338

/ Active, not recruitingPhase 2IIT

Telitacicept in the Treatment of Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits (PGNMID): A Prospective, Single-Arm Study

This single-center, prospective, single-arm study will evaluate the efficacy and safety of telitacicept in 10 adults with biopsy-proven proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
Eligible participants (≥18 y, ≥1 g/day proteinuria, eGFR ≥20 mL/min/1.73 m²) will receive 160 mg telitacicept subcutaneously once weekly for 24 weeks after a 12-week run-in on maximally tolerated ACEi/ARB.
The primary endpoint is change in 24-hour urine protein from baseline to Week 24. Secondary endpoints include changes in eGFR, urine red-blood-cell count, and serum immunoglobulin/complement levels. Safety will be monitored throughout.
Recruitment is planned from May 2025 to May 2027 at Peking University First Hospital.

Start Date12 Jul 2025

Sponsor / Collaborator

Peking University First Hospital

100 Clinical Results associated with Telitacicept

100 Translational Medicine associated with Telitacicept

100 Patents (Medical) associated with Telitacicept

129

Literatures (Medical) associated with Telitacicept

31 Dec 2025·RENAL FAILURE

Efficacy and safety of telitacicept in IgA nephropathy: a real-world study

Article

Author: Qin, Wei ; Tan, Jiaxing ; Tang, Yi ; Wang, Siqing ; Qin, Aiya ; Yang, Dandan ; Dong, Lingqiu

BACKGROUND:

IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and specific therapeutic methods for IgAN are limited. Telitacicept is a humanized fusion protein composed of a transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor and human IgG.

AIM:

To evaluate the efficacy and safety of telitacicept in adult patients with IgAN in a real-world study.

METHODS:

Biopsy-proven IgAN patients with 24-hour proteinuria greater than 0.5 g/d who received 240 mg telitacicept weekly were recruited for this study and 1:1:1 matched with patients who received supportive treatment only or immunosuppressive treatment by propensity score matching. The primary outcome was the change from baseline in 24-hour proteinuria over the 3-month follow-up.

RESULTS:

Twenty-one patients in each group were enrolled. Telitacicept reduced median proteinuria by 0.72 g/d (54.6%) from baseline, compared with a reduction of 0.18 g/d (20%) in the supportive treatment group and 1.12 g/d (72.1%) in the immunosuppressive treatment group. Preserved eGFR levels were observed in the telitacicept group, whereas eGFR levels decreased in the other two groups. No serious adverse events were observed in the telitacicept treatment group.

CONCLUSION:

Telitacicept may be an effective treatment for IgAN patients by reducing proteinuria and preserving eGFR, and showed a favorable safety profile.

11 Aug 2025·CLINICAL AND EXPERIMENTAL MEDICINE

Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study.

Article

Author: Chen, Cheng ; Wei, Zhongping ; Li, Xiaoqing ; Chen, Ju ; Chen, Xinghua ; Zhang, Lu ; Cheng, Hui ; Shu, Huapan ; Wang, Yujuan ; Wang, Huiming ; Song, Yuan ; Liang, Wei

Presently, no specific therapies have been recognized for immunoglobulin A nephropathy (IgAN). Mycophenolate mofetil (MMF) has been verified effective for Chinese patients with IgAN. Telitacicept is a full-human TACI-FC fusion preventing B cells maturation and activation, and it has been proven to be beneficial for IgAN in a phase II clinical trial. This study was designed to observe the efficacy and safety of telitacicept plus low-dose MMF for IgAN treatment. This retrospective cohort study included 24 patients with IgAN, and patients were treated with telitacicept plus MMF. The primary outcome was settled as the changing in proteinuria and estimated glomerular filtration rate (eGFR). The subordinate outcome was set as the changing in hematuria. The mean follow-up time was 23 months. The median baseline proteinuria was 2.5 (1.74, 6.58) g/d, and eGFR was 94.97 (56.8, 120.67) mL/min/1.73 m². There were noteworthy reductions in proteinuria at 3, 6, 9, 12, 15, 18, 21 and 24 months when compared to the baseline levels [1.45 (0.78, 1.8) g/d [p = 0.0122], 0.505 (0.26, 0.99) g/d [p < 0.0001], 0.48 (0.28, 0.76) g/d [p < 0.0001], 0.3 (0.17, 0.85) g/d [p < 0.0001], 0.23 (0.18, 0.575) g/d [p < 0.0001], 0.18 (0.12, 0.325) g/d [p < 0.0001], 0.14 (0.105, 0.22) g/d [p < 0.0001] and 0.14 (0.103, 0.278) g/d [p < 0.0001]]. All patients maintained stable eGFR during follow-up times. Besides, telitacicept plus MMF remarkably alleviated the hematuria. Telitacicept plus MMF treatment led to not only remarkable clinically significant reduction in proteinuria and hematuria, but also stable serum creatinine value of patients with IgAN without adverse side effects.

01 Aug 2025·Clinical Kidney Journal

Telitacicept treatment for recurrent IgA nephropathy after kidney transplantation

Article

Author: Zhong, Shan ; Yang, Hongji ; Xu, Lichen ; Hou, Yifu ; Di, Wenjia ; Zhang, Ping ; Wang, Fang ; Li, Guisen ; Wu, Shukun

ABSTRACT:

Background:

Immunoglobulin A nephropathy (IgAN) is frequently recurrent after kidney transplantation, posing significant challenges in management. Current treatments, including glucocorticoids and immunosuppressants, have shown limited effectiveness in treating recurrent IgAN. A phase 2 clinical trial indicated that telitacicept could reduce proteinuria in patients with primary IgAN. In this report, we conduct a retrospective analysis to assess the efficacy and safety of telitacicept in treating recurrent IgAN among kidney transplant recipients.

Methods:

A retrospective cohort study was conducted from August 2023 to April 2025. Patients with biopsy-proven recurrent IgAN following kidney transplantation who were treated with telitacicept were included. Clinical data were collected from hospitalization records and outpatient follow-ups. The primary outcome was proteinuria reduction at 6 months, with extended evaluation at 12 months. Renal function changes were also observed.

Results:

Ten patients with recurrent IgAN were treated with telitacicept. After a 6-month follow-up, two patients achieved complete remission (CR), and two patients reached partial remission (PR). Furthermore, six patients (60%) experienced a reduction of over 30% in proteinuria by the end of the 6-month treatment period. At 9-month follow-up, one patient reached CR, two patients reached PR and five patients (50%) showed a reduction in proteinuria. By the 12-month follow-up, serum creatinine levels and estimated glomerular filtration rate remained stable in nine patients. Furthermore, the treatment also effectively reduced urine red blood cell counts.

Conclusions:

Telitacicept shows promising safety and efficacy in lowering proteinuria for patients with recurrent IgAN following kidney transplantation.

News (Medical) associated with Telitacicept

19 Aug 2025

·www.prnewswire.com

RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries

YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd. ("Santen"). Under the agreement, Santen China has obtained exclusive rights to develop, manufacture, and commercialize RC28-E in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan) as well as in South Korea, Thailand, Vietnam, Singapore, the Philippines, Indonesia, and Malaysia. RemeGen will retain global exclusive rights to RC28-E outside these regions. RemeGen will receive upfront payment of RMB 250 million, development and regulatory milestone payments of up to RMB 520 million, and sales milestone payments of up to RMB 525 million. In addition, RemeGen will be entitled to tiered royalties based on net sales of the product in the licensed territories. RC28-E is a VEGF/FGF dual-target fusion protein drug for ocular neovascular diseases, independently developed by RemeGen. On May 7, 2025, the Phase II clinical trial results of RC28-E for diabetic macular edema (DME) were presented as an oral report at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting. The study demonstrated that RC28-E significantly improved best-corrected visual acuity (BCVA) and reduced central subfield thickness (CST), and was also well tolerated in patients with DME. In 2023, RemeGen initiated Phase III clinical trials for RC28-E in wet age-related macular degeneration (wAMD) and DME. RemeGen plans to submit a Biologics License Application (BLA) for the DME indication in China in the second half of 2025, followed by a BLA for wAMD in mid 2026. Dr. Jianmin Fang, CEO of RemeGen, stated: "Santen brings over 130 years of expertise in ophthalmology and a robust global sales network spanning 60+ countries and regions. RC28-E, a Class 1 proprietary drug developed by RemeGen, is approaching the critical stage of BLA submission. We believe this collaboration will fully leverage the strengths of both parties to maximize the potential of RC28-E, providing innovative and effective solutions for retinal diseases. This partnership not only lays a solid foundation for the future commercialization of RC28-E but also reflects international recognition of RemeGen's capabilities in ophthalmic drug development. We look forward to jointly advancing this breakthrough therapy with Santen to open a new chapter in eye care." Takeshi Ito, President & CEO of Santen, commented: "RemeGen has demonstrated outstanding capabilities and innovation in the field of novel drug development. As RemeGen's flagship pipeline in ophthalmology, RC28-E offers differentiated advantages by simultaneously targeting angiogenesis and fibrosis, potentially providing a new therapeutic approach and innovative option for the treatment of fundus diseases. Looking ahead, Santen are committed to strengthening cooperation and collaboration with all partners, by global-to-local synergy, to help advancing the high-quality development in ophthalmology, uncovering and addressing unmet patient needs, and aiming to realize 'Happiness with Vision 'for all." About RemeGen: RemeGen Co., Ltd. is a leading innovative biopharmaceutical company in China，headquartered in Yantai Economic & Technological Development Zone, China, with R&D centers and subsidiaries in Beijing, Shanghai, and California, USA. The company achieved dual listings on Main Board of The Stock Exchange of Hong Kong Limited (2020) and Shanghai Stock Exchange STAR Market (2022), becoming a dual-listed "A+H" company. The company focuses on discovering, developing, manufacturing, and commercializing novel biologic drugs with independent intellectual property rights. Focusing on critical therapeutic areas including autoimmune diseases, oncology, and ophthalmology, the company has successfully developed multiple biologic drugs with significant clinical value. In 2021, RemeGen's first-in-class drugs – Telitacicept (for systemic lupus erythematosus, rheumatoid arthritis, and myasthenia gravis) and Disitamab Vedotin (for gastric cancer, urothelial carcinoma, and breast cancer) – were approved for marketing with a total of 6 approved indications across these two innovative therapies. The company has established a comprehensive commercialization system encompassing production and sales, successfully initiating commercial transformation in both domestic and international markets. For more information, please visit RemeGen's website About Santen Pharmaceutical Co., Ltd.: As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of "Happiness with Vision" by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, "Tenki ni sanyo suru," Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen's mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience "Happiness with Vision." For more information, please visit Santen's website SOURCE RemeGen Co., Ltd WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/inPhase 1Phase 2Drug ApprovalClinical Result

15 Aug 2025

·www.fiercepharma.com

Fierce Pharma Asia—Padcev's new breakthrough; China Alzheimer's drug's fate; Fosun's DPP1 deal

Padcev and Keytruda's perioperative win, Chinese regulators' decision on Green Valley's Alzheimer's drug, and Fosun's DPP1 licensing deal made our news this week. The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. Fosun Pharma is out-licensing its DPP1 inhibitor for up to $645 million. And more.1. Pfizer and Astellas' Padcev, plus Keytruda, delivers 'breakthrough' win in new bladder cancer useAfter making waves in first-line metastatic bladder cancer, the combination of Pfizer and Astellas’ Padcev and Merck & Co.’s Keytruda has shown it can extend lives when used as a perioperative treatment around surgery for patients with cisplatin-ineligible muscle-invasive bladder cancer, according to a readout from the phase 3 EV-303 study, which is also known as Keynote-905.2. China did not renew approval of controversial Alzheimer's drug, regulator's records showChina’s drug regulator did not renew the conditional nod for Green Valley Pharmaceuticals’ controversial Alzheimer’s disease med sodium oligomannate (GV-971), according to public records. The move followed a protracted review that stretched past the expiration date of the drug’s existing licensure, triggering a production and marketing halt in May.3. Expedition inks $645M pact to pocket Fosun's lung disease asset in knapsackInflammatory disease startup Expedition Therapeutics is paying $17 million upfront, plus up to $628 million in potential milestones, for ex-China rights to Fosun Pharma’s DPP1 inhibitor XH-S004. The deal was inked right before the FDA approved Insmed’s brensocatib as the first DPP1 inhibitor. The approved indication for Insmed's therapy is non-cystic fibrosis bronchiectasis.4. Aurobindo acquires US drugmaker Lannett for $250M to bolster 'reshoring' effortAurobindo is paying $250 million to buy Lannett, which is known for manufacturing attention-deficit/hyperactivity disorder medicines and generic liquids. “The acquisition strengthens Aurobindo’s ability to serve the U.S. generics space and provides strategic diversification into a specialized, high-value therapeutic category,” the Indian company said in an announcement.5. HLB taps new Elevar CEO amid liver cancer setbacks, new FDA push (Korea Biomedical Review)Korea’s HLB has tapped Byan Kim as CEO of Elevar Therapeutics. Kim will continue as co-CEO of HLB Innovation and CEO of another HLB subsidiary, Verismo Therapeutics. The move comes after Elevar and Jiangsu Hengrui Pharmaceuticals’ PD-1/VEGFR combination suffered repeated FDA setbacks in liver cancer and as Elevar prepares to file an approval for lirafugratinib in FGFR2-altered cholangiocarcinoma.Other News of Note:6. RemeGen's telitacicept meets the mark in ph. 3 Sjögren's study in China7. Indian API maker Garonit Pharma plans $46.1M antiseptic product plant in New York8. Shilpa wins India approval for world's first NAFLD med, company says (Regulatory tracker)

Drug ApprovalPhase 3AcquisitionLicense out/inExecutive Change

13 Aug 2025

·www.fiercepharma.com

RemeGen's telitacicept meets the mark in ph. 3 Sjögren's study in China

RemeGen did not provide a detailed breakdown of the data but noted that the results showed telitacicept “sustainably and effectively” improved patients’ symptoms, with a "favorable" safety profile to match. Vor Bio’s big bet on RemeGen’s autoimmune asset telitacicept appears well placed after the drug—already approved across three conditions overseas—delivered a late-stage win in a Sjögren's syndrome trial in China.The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on patients’ change from baseline at week 24 on a common measure of disease activity known as ESSDAI, RemeGen said Wednesday.The company did not provide a detailed breakdown of the data but noted that the results showed telitacicept “sustainably and effectively” improved patients’ symptoms, with a "favorable" safety profile to match.RemeGen will use the win to file for approval with China’s Center for Drug Evaluation, and the company says it plans to present the detailed pSS results at upcoming international medical conferences.Sjögren's syndrome is estimated to affect around 4 million to 10 million people in China, according to RemeGen. It’s estimated that around 4 million people live with Sjögren's in the U.S.The condition is a chronic inflammatory autoimmune disease that most frequently leads to dry eyes and dry mouth, though it can cause other debilitating symptoms throughout the body, too. Sjögren's can occur alone but is often accompanied by other immune system disorders like rheumatoid arthritis and lupus.Enter telitacicept, which works by targeting two cell-signaling molecules for B-lymphocyte development: B lymphocyte stimulator (BlyS) and A proliferation-inducing ligand (APRIL). The protein’s mode of action has informed RemeGen’s thesis that the drug could be used to treat a host of autoimmune diseases driven by B-cell-mediated responses, including Sjögren's. That line of thinking has already paid off handily for RemeGen in China, where telitacicept is approved in three autoimmune indications: Systemic lupus erythematosus (SLE), rheumatoid arthritis and generalized myasthenia gravis (gMG).Hoping to get in on the action, in late June, beleaguered Vor Bio paid $45 million upfront to acquire ex-China rights to telitacicept. The deal also includes an initial payment of $80 million in warrants that grant a RemeGen subsidiary roughly a 23% stake in Vor. Long-term, potential clinical and commercial milestones could earn RemeGen up to $4.1 billion from the deal.Aside from the fast track tag from the FDA, telitacicept is also cleared for a phase 3 trial in primary Sjögren's in the U.S., RemeGen said Wednesday.The licensing deal marked a major reversal for Vor, which had said in May that it was winding down its existing clinical and manufacturing operations and eliminating 95% of its workforce. Vor had been developing two lead cell therapy assets in acute myeloid leukemia and cited a “challenging fundraising environment” as the rationale behind its deep restructuring. While the late-stage trial win is no doubt good news for RemeGen, the Sjögren's community had reason to celebrate earlier this week after Novartis reported that its dual-mechanism, B-cell-depleting antibody ianalumab prevailed in two phase 3 studies in the autoimmune disease.Novartis claimed the wins marked the “first ever global phase 3 trials to demonstrate statistically significant reduction in disease activity for Sjögren's disease.” The Swiss pharma said it will use the results to inform approval applications with global regulators.

Phase 3License out/inClinical ResultCell TherapyDrug Approval

100 Deals associated with Telitacicept

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L04AA	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Myasthenia Gravis	China	RemeGen Co., Ltd.	20 May 2025
Rheumatoid Arthritis	China	RemeGen Co., Ltd.	16 Jul 2024
Systemic Lupus Erythematosus	China	RemeGen Co., Ltd.	09 Mar 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Sjögren's syndrome	Phase 3	China	RemeGen Co., Ltd.	03 Apr 2023
Lambert-Eaton Myasthenic Syndrome	Phase 3	China	RemeGen Co., Ltd.	28 Mar 2023
Glomerulonephritis, IGA	Phase 3	United States	RemeGen Co., Ltd.	18 Nov 2022
Neuromyelitis Optica	Phase 3	China	RemeGen Co., Ltd.	12 Jan 2018
Lupus Nephritis	Phase 2	China	RemeGen Co., Ltd.	17 Apr 2023
Multiple Sclerosis, Relapsing-Remitting	Phase 2	China	RemeGen Co., Ltd.	13 May 2021
Glomerulonephritis, Membranous	Phase 1	China	RemeGen Co., Ltd.	-
Interstitial lung disease due to connective tissue disease	IND Approval	China	RemeGen Co., Ltd.	19 May 2025
Nephrosis	IND Approval	China	RemeGen Co., Ltd.	22 Jul 2024
Immunoglobulin G4-Related Disease	IND Approval	China	RemeGen Co., Ltd.	17 Jun 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PRNewswire Manual	Phase 3	Primary Sjögren's syndrome	-	Telitacicept	cafbiuhcyz(purrrjxoxi) = The clinical results demonstrated that Telitacicept sustainably and effectively improved the clinical symptoms of Sjögren's syndrome patients, while showing favorable safety profile. xpidkuhmye (haojfipfjn ) Met	Positive	13 Aug 2025
				Placebo
NCT05737160 (PipelineReview) Manual	Phase 3	Myasthenia Gravis	114	Telitacicept 240 mg	rdhrcijaqe(lyzvqeudul) = ndvotuipeo pmqxsezjgj (uyltygymmt ) View more	Positive	08 Apr 2025
				Placebo	rdhrcijaqe(lyzvqeudul) = jzttzralna pmqxsezjgj (uyltygymmt ) View more
NCT06456580 (RemeMG, AAN2025) Manual	Phase 3	Myasthenia Gravis	114	Telitacicept 240 mg	vceidevyxm(qbdyyqpdsu) = owdepmbdda gniiuwgtff (flxfjolqko ) View more	Positive	05 Apr 2025
				Placebo	vceidevyxm(qbdyyqpdsu) = bzddfojuuj gniiuwgtff (flxfjolqko ) View more
NEWS Manual	Not Applicable	Glomerulonephritis, IGA	-	Telitacicept	prymdktcpv(tbbvzqcvvv) = vnywmgrbrl auqwmjlgbj (kmeyemphwu ) View more	Positive	15 Nov 2024
				Supportive treatment	prymdktcpv(tbbvzqcvvv) = xyvexppktc auqwmjlgbj (kmeyemphwu ) View more
NCT02885610 (Pubmed \| Ann Rheum Dis) Manual	Phase 2	Systemic Lupus Erythematosus	249	Telitacicept 80 mg	rybonjacag(wponskclxm) = ypxkwgtwhp wpkasnlatz (tvfyfuhlqj )	Positive	01 Apr 2024
				Telitacicept 160 mg	rybonjacag(wponskclxm) = qfjrzrzwpk wpkasnlatz (tvfyfuhlqj )
NCT04078386 (Literature) Manual	Phase 2	Primary Sjögren's syndrome	42	telitacicepttelitacicept 160 mg	lgpmaqajgp(peuulpeetg) = None tfaqpujtmw (yhkzxirbbh ) View more	Positive	01 Mar 2024
				telitacicepttelitacicept 240 mg
NCT03016013 (ACR2023) Manual	Phase 3	Rheumatoid Arthritis	479	Telitacicept 160 mg	odkynrjjbx(clgwlywivu) = jsvmcppdmp zxsmzghtvv (gwlgmnmraa ) View more	Positive	24 Oct 2023
				Placebo	odkynrjjbx(clgwlywivu) = nahsdpxwhv zxsmzghtvv (gwlgmnmraa ) View more
NCT04078386 (Corporate Publications) Manual	Phase 2	Primary Sjögren's syndrome	42	placebo	axdorihmbz(dqbniiehpy) = rkdybwurov ctocqhswnb (kewgsciruf, 4.55)	Positive	17 Jul 2023
				Telitacicept 160 mg	axdorihmbz(dqbniiehpy) = jacroqawud ctocqhswnb (kewgsciruf, 2.73)
EULAR2023	Phase 3	Systemic Lupus Erythematosus ANA/anti-dsDNA \| C3 \| C4 ... View more	335	Telitacicept 160 mg	mpmeqnnqne(couoixjitv) = mlblbeusrx qrbddwvxlw (ieaqmoatdr )	Positive	31 May 2023
				Placebo	mpmeqnnqne(couoixjitv) = wzjdrpvedk qrbddwvxlw (ieaqmoatdr )
Pubmed Manual	Not Applicable	Systemic Lupus Erythematosus	20	Telitacicept	vuvrhxofad(gluydcqrra) = kvfapoqxds rjuvdidbmg (xndnsxtrbo ) View more	Positive	23 Nov 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis